⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PVLA News
Palvella Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
PVLA
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
PVLA
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
globenewswire.com
PVLA
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
globenewswire.com
PVLA
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
globenewswire.com
PVLA
Form 8-K
sec.gov
PVLA